All In Biotech

Drug Trial Radar · NCT03482635

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

98

Actual

Start

Mar 27, 2018

Primary completion

May 18, 2020

Study completion May 18, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are * to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II) * to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III) * To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.

Conditions

  • Colitis, Ulcerative

Interventions

  • SpesolimabDrug

    Solution for infusion

  • PlaceboDrug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With Clinical Remission at Week 12Time frame: At week 12.

Locations

54 sites in 12 countries. Site status is shown where the registry gives one.

  • Medical Research Center of Connecticut, LLC

    Hamden, Connecticut

  • University of Miami

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Emory University

    Atlanta, Georgia

  • Atlanta Center for Gastroenterology, P.C.

    Decatur, Georgia

  • University of Chicago

    Chicago, Illinois

  • Columbia University Medical Center-New York Presbyterian Hospital

    New York, New York

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Digestive Disease Specialists Inc

    Oklahoma City, Oklahoma

  • Baylor College of Medicine

    Houston, Texas

  • Southern Star Research Institute, LLC

    San Antonio, Texas

  • Texas Digestive Disease Consultants - Southlake

    Southlake, Texas

  • Hunter Holmes McGuire VA Medical Center

    Richmond, Virginia

  • Ordensklinikum Linz GmbH - Barmherzige Schwestern

    Linz, Austria

  • AKH - Medical University of Vienna

    Vienna, Austria

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

  • University of Manitoba - Health Sciences Centre

    Winnipeg, Manitoba, Canada

  • Victoria Hospital (LHSC)

    London, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Universitätsklinikum Aachen, AöR

    Aachen, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Essen AöR

    Essen, Germany

  • Klinikum Esslingen GmbH

    Esslingen am Neckar, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Azienda Ospedaliera Universitaria di Padova

    Padova, Italy

  • Istituto Clinico Humanitas

    Rozzano (MI), Italy

  • Toho University Sakura Medical Center

    Chiba, Sakura, Japan

  • Sapporo Tokushukai Hospital

    Hokkaido, Sapporo, Japan

  • Sapporo Higashi Tokushukai Hospital

    Hokkaido, Sapporo, Japan

  • Hyogo College of Medicine Hospital

    Hyogo, Nishinomiya, Japan

  • Sameshima Hospital

    Kagoshima, Kagoshima, Japan

  • Ofuna Chuo Hospital

    Kanagawa, Kamakura, Japan

  • Tokyo Medical and Dental University

    Tokyo, Bunkyo-ku, Japan

  • Kitasato Institute Hospital

    Tokyo, Minato-ku, Japan

  • Tokyo Yamate Medical Center

    Tokyo, Shinjuku, Japan

  • Health Center of Mother, Child and Youth Sp.z o.o.

    Warsaw, Poland

  • Central Clinical Hospital MSWiA, Internal Diseases, Warsaw

    Warsaw, Poland

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.